Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly (NYSE:LLY ... The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it? The order signed on May 12 aims to align U.S. drug prices ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

The president said his executive order will require pharmaceutical companies to price drugs in the U.S. in line with the lowest price they charge in other countries.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

However, President Trump has publicly stated that pharmaceutical import tariffs are on the way. Earlier this year, he proposed levying 25% tariffs on imported drugs. Lilly CEO Dave Ricks acknowledged ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald Trump would sign an order lowering some drug prices. A surprise trade ...